Compare MP & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MP | DVA |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Misc Health and Biotechnology Services |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.2B |
| IPO Year | N/A | 1995 |
| Metric | MP | DVA |
|---|---|---|
| Price | $68.63 | $108.85 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 4 |
| Target Price | $70.92 | ★ $145.00 |
| AVG Volume (30 Days) | ★ 8.3M | 782.5K |
| Earning Date | 02-19-2026 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.63 |
| EPS | N/A | ★ 9.76 |
| Revenue | $232,742,000.00 | ★ $13,317,965,000.00 |
| Revenue This Year | $34.68 | $6.50 |
| Revenue Next Year | $137.40 | $2.97 |
| P/E Ratio | ★ N/A | $10.89 |
| Revenue Growth | ★ 26.44 | 5.14 |
| 52 Week Low | $18.64 | $101.00 |
| 52 Week High | $100.25 | $179.60 |
| Indicator | MP | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 61.36 | 43.91 |
| Support Level | $61.52 | $103.48 |
| Resistance Level | $71.69 | $106.38 |
| Average True Range (ATR) | 4.71 | 3.31 |
| MACD | 0.95 | -0.16 |
| Stochastic Oscillator | 85.18 | 53.37 |
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.